5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 3.24▼ | 3.24▼ | 3.24▼ | 3.30▼ | 3.55▼ |
MA10 | 3.22▲ | 3.26▼ | 3.26▼ | 3.52▼ | 4.87▼ |
MA20 | 3.27▼ | 3.29▼ | 3.31▼ | 3.62▼ | 6.77▼ |
MA50 | 3.38▼ | 3.52▼ | 3.59▼ | 5.25▼ | 13.33▼ |
MA100 | 3.52▼ | 3.97▼ | 3.78▼ | 7.04▼ | 38.81▼ |
MA200 | 3.90▼ | 4.38▼ | 5.34▼ | 10.48▼ | 74.27▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.009▲ | 0.011▲ | 0.014▲ | 0.053▲ | 0.337▲ |
RSI | 42.700▼ | 36.630▼ | 36.980▼ | 39.381▼ | 27.759▼ |
STOCH | 61.139 | 41.305 | 40.649 | 6.809▼ | 10.443▼ |
WILL %R | -58.824 | -61.111 | -62.162 | -96.275▼ | -97.331▼ |
CCI | -16.677 | -72.994 | -73.338 | -72.198 | -119.238▼ |
Saturday, June 07, 2025 05:00 PM
Therefore, it is recommended to visit the company's website for up to date information. Nasdaq Insider Activity page provides trading information of corporate insiders (officers, directors and any ...
|
Thursday, May 29, 2025 06:53 AM
allowing an investor to gain exposure to the trends within that segment. According to data from Benzinga Pro, ALZN has a 52-week high of $135.54 and a 52-week low of $3.06.
|
Tuesday, May 27, 2025 05:00 PM
General Hospital for 5 Phase II clinical trials of AL001 ATLANTA, August 19, 2024--Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 3.39 | 3.43 | 3.17 | 3.24 | 742,800 |
12/06/25 | 3.31 | 3.35 | 3.05 | 3.19 | 283,100 |
11/06/25 | 3.35 | 3.40 | 3.29 | 3.34 | 215,300 |
10/06/25 | 3.37 | 3.375 | 3.29 | 3.30 | 138,356 |
09/06/25 | 3.60 | 3.64 | 3.37 | 3.45 | 197,467 |
06/06/25 | 3.62 | 3.76 | 3.53 | 3.62 | 227,275 |
05/06/25 | 3.85 | 4.00 | 3.68 | 3.72 | 301,026 |
04/06/25 | 3.75 | 4.02 | 3.56 | 3.97 | 602,552 |
03/06/25 | 3.75 | 4.30 | 3.70 | 3.83 | 2,458,588 |
02/06/25 | 3.90 | 3.9118 | 3.50 | 3.50 | 543,630 |
|
|
||||
|
|
||||
|
|